Charles River and Lundbeck To Use AI-Powered Logica® To Speed Up Breakthroughs in Neurological Drugs

Charles River Laboratories International, Inc. announced its partnership with H. Lundbeck A/S (Lundbeck) to leverage Logica® in order to progress the research on critical brain disease. Logica is an AI-driven solution for drug discovery that helps in translating biological data into an enhanced pre-clinical candidates by integrating AI-powered Opal Computational Platform™ by Valo Health, alongwith Charles River’s prowess in preclinical development and drug discovery. With this agreement, Lundbeck further plans to utilize Logica in an effort to develop advanced small molecules, having an aim towards fostering new and effective treatments in the field of neurological treatments. 

Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River, said in a statement, “We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease. Logica’s integrated, AI-augmented process allows us to be an agile partner, and combined with Lundbeck’s industry-leading neurology expertise, we look forward to a successful collaboration.”

Tarek Samad, Senior Vice President and Head of Global Research at Lundbeck, also commented “To make a significant impact on neurological diseases today, you need to be able to work on unprecedented molecular targets with causal biology. Partnering with Logica will allow us to use a unique tool set, including AI-driven approaches, to overcome drug design challenges which often slow down the translation of promising targets into drug candidates.”